Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
This page provides a historical news archive for ZimVie Inc. (formerly Nasdaq: ZIMV), a company that described itself as a global life sciences leader in the dental and dental implant market. The news coverage reflects ZimVie’s activities while it was a publicly traded manufacturer and developer of dental implants, biomaterials, and digital workflow solutions for tooth replacement and restoration procedures.
Readers can review company-issued announcements on topics such as quarterly financial results, strategic agreements, product launches, and corporate transactions. For example, ZimVie reported first and second quarter 2025 financial results, including net sales from continuing operations and non-GAAP measures like adjusted EBITDA and adjusted diluted earnings per share. The company also communicated guidance for full-year financial performance while it remained public.
The archive includes news about ZimVie’s role in digital dentistry, such as the launch of the RealGUIDE dental implant software suite and the Implant Concierge service in Japan. These releases describe a digital implant ecosystem that supports implant planning, surgical guide design, and restorative workflows, as well as virtual outsourcing services for implant treatment planning and guided surgery. Other news items highlight an exclusive distribution agreement with Osstem Implant in China, under which Osstem Implant has exclusive commercial responsibility for ZimVie implant systems in the Chinese market.
A significant portion of the news flow in 2025 relates to ZimVie’s agreement to be acquired by an affiliate of ARCHIMED. The company announced the definitive merger agreement, subsequent stockholder approval at a special meeting, and the completion of the transaction. In its October 20, 2025 release, ZimVie stated that, following the closing of the acquisition, its common stock no longer trades on the Nasdaq exchange and the company became privately held. Investors and researchers can use this news history to understand ZimVie’s strategic direction, financial communication, and the steps leading to its transition from a listed company to a private entity.
ZimVie Inc. began trading on the Nasdaq under the symbol ZIMV on March 1, 2022, marking its debut as an independent company following its separation from Zimmer Biomet. This strategic move aims to enhance the company's focus on its Dental and Spine product platforms, which together represent a $20 billion addressable market. ZimVie appointed a new Board of Directors with diverse healthcare experience to guide its growth and shareholder value.